Biopharma PEG Scientific Inc.

On April 22, the FDA approved sacituzumab govitecan for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.

Ludwig-Maximilians-Universitaet (LMU) in Munich researchers have developed a novel type of nanoparticle that efficiently and selectively kills cancer cells, thus opening up new therapeutic options for the treatment of tumors.

Immunotherapy, treatment of cancer with substances that strengthen the body's natural immune response, is the most prominent topic within melanoma research, accounting for 4.9 percent of papers published between 2013 and 2018.

Two new medications commonly used to treat type 2 diabetes are similar in their ability to reduce major heart complications, including heart attack, stroke and death from cardiovascular disease, according to research accepted for presentation at ENDO...

Physician-scientists in the Cancer Center at Children's Hospital of Philadelphia (CHOP) have developed a preclinical, potent therapy attached to an antibody that targets a surface protein expressed in most childhood neuroblastomas, effectively killing...

PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins.

Polyethylene glycol (PEG) is a biocompatible, synthetic, hydrophilic polyether compound that has many applications, mostly in the medical industry, but also in the chemical and industrial sectors.

Hydrophilic poly(ethylene glycol) or PEG-linkers are particularly attractive as a linker for conjugation.

Type 2 diabetes is the most common form of diabetes. Semaglutide is an agonist of glucagon-like peptide-1 (GLP-1) receptor that is developed to treat type 2 diabetes. It reduces blood sugar via increasing the production of insulin.